Q2 sales declined 4% year-over-year, but order backlog rose 44.5% and H1 order intake grew 30%. Adjusted EBITDA was positive, though one-off costs impacted reported results. 2024 guidance targets 30–40% EBITDA growth and 8–12% organic growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.